BioSig Technologies, Inc. Stock price

Equities

BSGM

US09073N3008

Advanced Medical Equipment & Technology

Delayed Nasdaq 02:17:03 2024-03-28 pm EDT 5-day change 1st Jan Change
0.68 USD -6.85% Intraday chart for BioSig Technologies, Inc. +27.36% -85.79%
Sales 2023 * 100K Sales 2024 * 1.5M Capitalization 6.81M
Net income 2023 * -27M Net income 2024 * -13M EV / Sales 2023 * 68.1 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 4.54 x
P/E ratio 2023 *
-0.2 x
P/E ratio 2024 *
-0.49 x
Employees 47
Yield 2023 *
-
Yield 2024 *
-
Free-Float 77.44%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.53%
1 week+27.36%
Current month-1.60%
1 month-10.00%
3 months-85.77%
6 months-85.97%
Current year-85.79%
More quotes
1 week
0.46
Extreme 0.4555
0.77
1 month
0.46
Extreme 0.4555
0.78
Current year
0.26
Extreme 0.2619
4.75
1 year
0.26
Extreme 0.2619
16.50
3 years
0.26
Extreme 0.2619
49.00
5 years
0.26
Extreme 0.2619
124.30
10 years
0.26
Extreme 0.2619
124.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 Feb. 26
Chief Administrative Officer 51 09-02-23
Chief Tech/Sci/R&D Officer 74 09-02-23
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 74 09-02-23
Chief Executive Officer 58 Feb. 26
More insiders
Date Price Change Volume
24-03-28 0.68 -6.85% 238 300
24-03-27 0.73 +55.32% 353,438
24-03-26 0.47 -14.36% 100,329
24-03-25 0.5488 +1.82% 46,703
24-03-22 0.539 +1.70% 64,097

Delayed Quote Nasdaq, March 28, 2024 at 02:17 pm EDT

More quotes
BioSig Technologies, Inc. is a medical technology company. The Company is focused on commercializing an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Its product PURE EP System is a non-invasive class II device consisting of a combination of hardware and software designed to provide signal clarity and precision for real-time visualization of intracardiac signals, paving the way for personalized patient care. PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated with signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.73 USD
Average target price
50 USD
Spread / Average Target
+6,749.32%
Consensus
  1. Stock
  2. Equities
  3. Stock BioSig Technologies, Inc. - Nasdaq